Related Experiment Video

Updated: Sep 26, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

733

In the Tumor Microenvironment, ETS1 Is an Oncogenic Immune Protein: An Integrative Pancancer Analysis

Zixuan Wu1, Yanhui Jiang1, Xuyan Huang1

  • 1Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China.

Evidence-Based Complementary and Alternative Medicine : Ecam
|April 25, 2022
PubMed
Abstract

Insights

ETS1 (ETS proto-oncogene 1, transcription factor) shows high expression in tumors and correlates with poor survival. While linked to immune responses, ETS1 did not predict immunotherapy success, suggesting it as a prognostic biomarker and potential therapeutic target.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • ETS proto-oncogene 1, transcription factor (ETS1) has potential in cancer immunotherapy.
  • The underlying mechanisms of ETS1's therapeutic role require further investigation.

Purpose of the Study:

  • To investigate the association between ETS1 expression and the tumor immune microenvironment.
  • To explore the role of ETS1 in cancer immunity and its potential as a therapeutic target.

Main Methods:

  • Analysis of ETS1 genetic alterations, expression patterns, and survival data from TCGA, GEO, and IMvigor210 datasets.
  • Exploration of ETS1's relationship with the tumor microenvironment (TME), immune components, and major histocompatibility complex.
  • Evaluation of ETS1 in relation to immunotherapeutic response across three distinct cohorts.

Main Results:

  • ETS1 expression is elevated in tumor tissues and associated with poorer overall survival.
  • ETS1 expression correlates with immune cell infiltration, immune modulators, and immune-related pathways.
  • No statistically significant correlation was found between ETS1 and the response to immunotherapy.

Conclusions:

  • ETS1 serves as a potential prognostic biomarker for various cancers.
  • ETS1 represents a prospective therapeutic target for cancer immunotherapy, particularly in specific cancer types like KIRP, MESO, BLCA, KIRC, and THYM.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
687
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K